Aion Therapeutic Inc.
AION
CNSX
| 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 164.50K | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 164.50K | -- | -- | -- | -- |
| Cost of Revenue | 43.20K | -- | -- | -- | -- |
| Gross Profit | 121.30K | -- | -- | -- | -- |
| SG&A Expenses | 280.50K | 198.20K | 161.50K | 124.10K | 137.10K |
| Depreciation & Amortization | 11.10K | -- | -- | 100.00 | 4.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 334.70K | 198.20K | 161.50K | 124.20K | 141.50K |
| Operating Income | -170.30K | -198.20K | -161.50K | -124.20K | -141.50K |
| Income Before Tax | -279.90K | -133.60K | -191.10K | -534.10K | -160.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -279.90K | -133.60K | -191.10K | -534.10K | -160.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -279.90K | -133.60K | -191.10K | -534.10K | -160.00K |
| EBIT | -170.30K | -198.20K | -161.50K | -124.20K | -141.50K |
| EBITDA | -169.50K | -- | -- | -124.10K | -137.10K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 315.90M | 190.32M | 168.81M | 147.27M | 147.30M |
| Average Diluted Shares Outstanding | 315.90M | 190.32M | 168.81M | 147.27M | 147.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
